ALC-919 For The Treatment Of Common Warts

NCT ID: NCT02483455

Last Updated: 2016-03-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2015-10-31

Brief Summary

This is a single-center, randomized, double blind, vehicle-controlled phase 2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment.

Detailed Description

This is a single-center, randomized, double blind, vehicle-controlled phase-2 study of subjects 8 years of age and older with Common Warts (Verruca vulgaris) who desire treatment. A total of four visits are planned including one baseline and three follow-ups. Screening will be done at Visit 1 (Baseline) and all safety and efficacy measurements will be made at all subsequent visits (Visits 2-4).

The primary objective is to evaluate the efficacy of twice daily-applied ALC-919 vs. vehicle in male and female subjects 8 years of age and older with Common Warts (Verruca vulgaris). The primary outcome measure is complete resolution of lesions at the 12 week visit. Secondary outcome measures will include the change in lesion count at the 12 week visit, improvement in the Global Aesthetic Improvement Scale score at the 12 week visit and the safety and tolerability profile of the treatment arm compared to the vehicle arm at each study visit. The safety will be assessed using clinical cutaneous safety exams that will report scaling, dryness and erythema on a scale of 0-3 (0= absent, 1=mild. 2=moderate, 3=severe). Tolerability will be assessed by having subjects answer the treatment tolerability questions at each visit during the treatment period. The tolerability question will be assessed using a 0-3 scale for itching, burning, and stinging.

Conditions

Verruca Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

ALC-919 Topical Solution

ALC-919 Topical Solution will be applied twice daily to study area for the treatment of Common Warts

Group Type: EXPERIMENTAL

2014-ALC-919-US

Intervention Type: DRUG

A topical solution to be applied twice daily for the treatment of Common Warts

Vehicle-Control Topical Solution

Vehicle-Control Topical Solution will be applied twice daily to study area for the treatment of Common Warts

Group Type: PLACEBO_COMPARATOR

Vehicle-Control Topical Solution

Intervention Type: DRUG

A topical solution to be applied twice daily for the treatment of Common Warts

Interventions

2014-ALC-919-US

A topical solution to be applied twice daily for the treatment of Common Warts

Intervention Type: DRUG

Vehicle-Control Topical Solution

A topical solution to be applied twice daily for the treatment of Common Warts

Intervention Type: DRUG

Other Intervention Names

ALC-919; ALC-Vehicle-Control

Eligibility Criteria

Inclusion Criteria

• Males or females aged 8 years or older;
• Individuals with at least 1, but not exceeding 10 Common Wart(s) (Verruca vulgaris) to be treated;
• Individuals whose treatment area is located anywhere on the body except for the following prohibited areas which include: the eye area (including eyelids), lips, mouth cavity, nasal cavity, inner ear, palms of the hands (including periungual area), soles of the feet (including periungual area), or the anogenital area;
• Individuals who are generally in good health as determined by the Principal Investigator;
• Willingness and ability to read, understand, and sign the IRB-approved informed consent form in English after the nature of the study has been fully explained and questions have been answered;
• Individuals who are willing to not start any new products OTC or prescription treatments and discontinue any treatment the Principal Investigator feels may interfere with the evaluation of the test products;
• Individuals who are willing to avoid using cosmetic products, creams, salves, or ointments to the treatment area(s);
• Individuals who are willing and able to thoroughly follow the product use instructions, attend all the scheduled visits and successfully complete the study;
• Individuals who are willing and able to not begin any office based treatments for the duration of the study;
• Individuals who are determined to be free of any systemic or dermatologic disorder, which, in the opinion of the Principal Investigator, will interfere with the study results;
• Female subjects determined to be of child-bearing potential must indicate to the best of their knowledge they are not pregnant and/or lactating nor do they intend to become pregnant during their participation in the study;
• Female subjects with reproductive potential must agree to practice medically acceptable form of birth control during the study;
• A female subject who is post-menopausal (amenorrhea for 12 months prior to the Baseline Visit) is not considered of reproductive potential.

Exclusion Criteria

• Have warts outside of the treatment area, the eye area (including eyelids), lips, mouth cavity, nasal cavity, inner ear, palms of the hands (including periungual area), soles of the feet (including periungual area), or the anogenital area) or any area that would interfere with study procedures or analyses;
• Have participated in an investigational trial within 30 days prior to enrollment;
• Have received cryotherapy in the treatment area within 30 days prior to enrollment;
• Have required or will require systemic intake of immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days prior to enrollment or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed
• Have any uncontrolled current infection;
• Female subject who is pregnant, lactating planning to become pregnant, or is breastfeeding;
• Have any chronic or acute medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk (such as an immunodeficiency or relevant genetic syndrome);
• Have any active malignancy or are undergoing treatment for any malignancy other than non-melanoma skin cancer;
• Individuals who are mentally incompetent, unable or not willing to give written informed consent or meet study requirements;
• Subjects viewed by the Principal Investigator as not being able to complete the study.
• Subjects have a known history of irritation or allergy caused by povidone-iodine
• Have an excessive number of Common Warts (Verruca vulgaris), defined as greater than 10

• Minimum Eligible Age: 8 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Veloce BioPharma LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew Pollack, MD

Role: PRINCIPAL_INVESTIGATOR

Philadelphia Institute of Dermatology

Locations

Philadelphia Institute of Dermatology

Fort Washington, Pennsylvania, United States

Countries

United States

Other Identifiers

2014-ALC-919-US

Identifier Type: -

Identifier Source: org_study_id